Pulmatrix (NASDAQ:PULM) Shares Pass Below 50-Day Moving Average – Here’s What Happened

Pulmatrix, Inc. (NASDAQ:PULM)’s stock price crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $4.47 and traded as low as $2.36. Pulmatrix shares last traded at $2.36, with a volume of 33,436 shares traded.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulmatrix in a research note on Monday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Pulmatrix Stock Performance

The business’s 50-day moving average is $4.47 and its 200-day moving average is $5.26.

Pulmatrix (NASDAQ:PULM) last announced its earnings results on Thursday, October 16th. The biotechnology company reported ($0.24) earnings per share for the quarter.

Institutional Investors Weigh In On Pulmatrix

A hedge fund recently raised its stake in Pulmatrix stock. SBI Securities Co. Ltd. raised its stake in Pulmatrix, Inc. (NASDAQ:PULM) by 15.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 60,565 shares of the biotechnology company’s stock after acquiring an additional 8,208 shares during the period. SBI Securities Co. Ltd.’s holdings in Pulmatrix were worth $418,000 as of its most recent SEC filing. Institutional investors and hedge funds own 11.84% of the company’s stock.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).